Brief: Assembly Bio Selects Fourth Hbv Core Inhibitor Candidate For Advancement Into Clinical Development

Assembly Biosciences

18/08/2021 13:17

Aug 18 (Reuters) - Assembly Biosciences Inc  ASMB.O :
    * ASSEMBLY BIO SELECTS FOURTH HBV CORE INHIBITOR CANDIDATE
FOR
ADVANCEMENT INTO CLINICAL DEVELOPMENT
    * ASSEMBLY BIOSCIENCES - SELECTED A FOURTH CORE INHIBITOR
CANDIDATE ABI-4334 (4334) TO ADVANCE INTO CLINICAL DEVELOPMENT
    * ASSEMBLY BIOSCIENCES - CONDUCTING PRECLINICAL WORK, WITH
AIM OF
COMPLETING REGULATORY FILINGS, INITIATING CLINICAL STUDIES AS
SOON AS POSSIBLE IN 2022

Source text for Eikon:  ID:nGNX5HQzFY 
Further company coverage:  ASMB.O 

 ((Reuters.Briefs@thomsonreuters.com;))